Glenmark unit gets tentative FDA nod for 2 drugs

Glenmark unit gets tentative FDA nod for 2 drugs

Mumbai: Glenmark Generics Ltd, a unit of Glenmark Pharmaceuticals Ltd, on Thursday said that its US unit received a tentative approval from the USFDA for two drugs.

The estimated market size of one of the drugs Pramipexole Dihydrochloride, the generic version of Boehringer Ingelheim’s Mirapex tablets, is estimated at $487 million, it said in a statement.

The second drug, Atomoxetine Hydrochloride, is used in the treatment of attention deficit or hyperactivity disorder, and has an estimated market size of $498 million, it added.

Close